Hepatitis B Virus Reactivation during Treatment with Multi-Tyrosine Kinase Inhibitor for Hepatocellular Carcinoma

Hepatitis B virus (HBV) reactivation is well documented in individuals with cancer who receive certain cytotoxic or immunosuppressive therapies including rituximab treatment. As a general rule, the risk is greatest upon withdrawal of chemotherapy. The risk ranges from approximately 20 to 50% among H...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiba, Satoshi, Kondo, Shunsuke, Ueno, Hideki, Morizane, Chigusa, Ikeda, Masafumi, Okusaka, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2012
Materias:
September, 2012
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492963/
https://www.ncbi.nlm.nih.gov/pubmed/23139664
http://dx.doi.org/10.1159/000342913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492963/
https://www.ncbi.nlm.nih.gov/pubmed/23139664
http://dx.doi.org/10.1159/000342913

Ejemplares similares